Bicara Therapeutics (BCAX) reported a Q1 net loss Monday of $0.93 per diluted share, widening from a loss of $0.68 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.65.
The company said it had cash, cash equivalents and marketable securities of $539.8 million as of March 31. Bicara expects its existing cash, cash equivalents and marketable securities to fund operations into H1 2029.